NVDA
NVIDIA
-- 135.099 TSLA
Tesla
-- 388.977 AMD
Advanced Micro Devices
-- 114.785 RGTI
Rigetti Computing
-- 9.4988 TSM
Taiwan Semiconductor
-- 205.060 
NEWS
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
Thursday, 9th January at 7:00 am
Transaction Expands Climb Bio's Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases
New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically Designed to Address Patient Needs
Preclinical Data Expected to be Shared Later in 2025
WELLESLEY HILLS, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ: CLYM) today announced it has entered into an exclusive license agreement with Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070, Mabworks) for rights to develop and commercialize MIL116 (now CLYM116), an anti-APRIL (A PRoliferation-Inducing Ligand) monoclonal antibody, in the territory outside of Greater China. Climb Bio believes CLYM116 is a potential best-in-class approach to address significant unmet need in patients with IgA nephropathy and other B-cell mediated diseases. This transaction furthers Climb Bio's goal of becoming a leader in developing new treatment options for immune-mediated diseases, complementing the Company's anti-CD19 antibody, budoprutug.
"Adding CLYM116 to our pipeline represents a pivotal moment for Climb Bio as we advance our ambition of becoming a leader in developing best-in-class treatments for patients with immune-mediated diseases," said Aoife Brennan, President and CEO of Climb Bio. "IgA nephropathy is the most common cause of glomerulonephritis worldwide, and we believe that inhibition of APRIL is both a clinically validated mechanism and potentially disease modifying approach for this indication. We look forward to rapidly advancing CLYM116 and sharing initial preclinical data later in 2025."
Thursday, 9th January at 7:00 am
Transaction Expands Climb Bio's Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases
New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically Designed to Address Patient Needs
Preclinical Data Expected to be Shared Later in 2025
WELLESLEY HILLS, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ: CLYM) today announced it has entered into an exclusive license agreement with Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070, Mabworks) for rights to develop and commercialize MIL116 (now CLYM116), an anti-APRIL (A PRoliferation-Inducing Ligand) monoclonal antibody, in the territory outside of Greater China. Climb Bio believes CLYM116 is a potential best-in-class approach to address significant unmet need in patients with IgA nephropathy and other B-cell mediated diseases. This transaction furthers Climb Bio's goal of becoming a leader in developing new treatment options for immune-mediated diseases, complementing the Company's anti-CD19 antibody, budoprutug.
"Adding CLYM116 to our pipeline represents a pivotal moment for Climb Bio as we advance our ambition of becoming a leader in developing best-in-class treatments for patients with immune-mediated diseases," said Aoife Brennan, President and CEO of Climb Bio. "IgA nephropathy is the most common cause of glomerulonephritis worldwide, and we believe that inhibition of APRIL is both a clinically validated mechanism and potentially disease modifying approach for this indication. We look forward to rapidly advancing CLYM116 and sharing initial preclinical data later in 2025."
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
6025Followers
70Following
64KVisitors
Follow
Discussing
Trump 2.0 countdown: What's the next big opportunity in the markets?
Trump is gearing up for a return to the political stage, and his "America First" tariff policies, along with his stance on cryptocurrency an
Michael McCarthy CCO
Jan 3 11:57
Ask a strategist - Trump's first day